Brief: University Of Calgary Joins The Phase Ii Trial Of Lsalt Peptide For The Treatment Of Complications In Hospitalized Covid-19 Patients
05/01/2021 12:54
Jan 5 (Reuters) - Arch Biopartners Inc ARCH.V :
* UNIVERSITY OF CALGARY JOINS THE PHASE II TRIAL OF LSALT
PEPTIDE
FOR THE TREATMENT OF COMPLICATIONS IN HOSPITALIZED COVID-19
PATIENTS
* ARCH BIOPARTNERS - CURRENTLY EXPLORING OPPORTUNITIES TO
ADD
ADDITIONAL CLINICAL SITES IN UNITED STATES, TURKEY & CANADA
Source text for Eikon: ID:nGNX1fF6NH
Further company coverage: ARCH.V
((reuters.briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide